Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Results for New Oxazolidinone Demonstrate Potency Against Superbugs

08.01.2002


Results for New Oxazolidinone Demonstrate Potency Against Gram-Positive Pathogens, including Superbugs



Unique compound AZD2563 shows promise for once-daily dosing

Chicago, IL World-wide data presented at the 41st Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC) show that AstraZeneca`s new oxazolidinone (AZD2563) is active against Gram-positive bacteria, including multi-drug resistant strains, and may have the added convenience of potential once-daily administration. In addition, the compound is more potent in vitro than linezolid, the only oxazolidinone currently on the market.


AZD2563 is the latest oxazolidinone under early-stage development for the treatment of infection with Gram-positive bacteria, including multiple-drug resistant strains. The promising novel oxazolidinone compound is being developed by AstraZeneca, and its microbiological data have been proven world-wide.

A major public health threat is posed by strains of Gram-positive bacteria that have evolved resistance to treatment: some are now resistant to many common antibiotics Overcoming Antimicrobial Resistance. (World Health Report on Infectious Diseases 2000. WHO, 2000.) Some only respond to recently developed intravenous anti-bacterials, or physicians have to rely on older and potentially more toxic drugs. Oxazolidinones are a new class of antibiotics with a novel mode of action and proven world-wide clinical data that meet the urgent need for new therapies for a spectrum of Gram-positive infections, including multiple-drug resistant strains.

Keith Williams, Global Product Director at AstraZeneca, said "Seventeen abstracts were selected for presentation at ICAAC. These contain important new data that suggest the unique structure of AZD2563 confers potency and potential once-daily dosing. It appears likely that AZD2563 will have a vital role to play in the fight against Gram-positive infections."

These initial results indicate that AZD2563 has excellent, targeted activity against all common Gram-positive bacteria, regardless of resistance to other classes of antibiotics. In one study (Turner PJ, Wookey A, Greenhalgh JM, Eastwood M, Clarke J. Investigations into the Antibacterial Spectrum of the New Oxazolidinone AZD2563. Poster presented at ICAAC 2001. Abstract F-1024.), the effectiveness of AZD2563 was measured against 838 clinical strains of bacteria, and its level of activity was compared to 14 antibiotics, including linezolid. Principal Investigator Dr Philip Turner commented: "For the majority of strains of streptococci and staphylococci, including methicillin-resistant staphylococci, AZD2563 was more potent in vitro than linezolid. Activities against strains of enterococci and pneumococci were comparable between AZD2563 and linezolid. Oxazolidinones are likely to evolve into a highly successful, widely-used class of antibiotics. AZD2563 will be available as an oral as well as an intravenous therapy and is a useful addition to the anti-Gram-positive armamentarium.”

Another study (Eliopoulis GM, Wennersten CB, Moellering Jr RC. Comparative In Vitro Activity of the New Oxazolidinone, AZD2563, against Enterococci. Poster presented at ICAAC 2001. Abstract F-1034). reinforces the suggestion that AZD2563 has a more powerful action than linezolid against some strains of bacteria. The activity of AZD2563 against 500 clinical isolates of enterococci was compared to linezolid and eight other antibiotics. The findings indicate that AZD2563 is generally two-fold more active in vitro than linezolid against enterococci, including multi-drug resistant strains. This suggests that AZD2563 is a potent oxazolidinone.

In addition, another study (Arundel PA. The New Oxazolidinone, AZD2563: Physiologically-based Pharmacokinetic Extrapolation to Man. Poster presented at ICAAC 2001. Abstract F-1039.) indicates that AZD2563 may offer the convenience of once-daily dosing. Currently, the only oxazolidinone on the market is indicated for twice-daily dosing in adults. In vivo data from AZD2563 were used to predict the behaviour of the compound in man. Human simulations based on experimental data predicted that AZD2563 is long-acting. Lead Investigator Dr Phil Arundel commented: "The fact that AZD2563 is long-acting and potent indicates that once-daily dosing is feasible. AZD2563 shows great promise in the fight against infections, including those caused by multi-drug resistant bacteria, and I await the results of further studies with interest".

Leslie Wheeler | alphagalileo

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>